CIK 0001253689 · Non-accelerated filer<br>Smaller reporting company
CRESCENT BIOPHARMA, INC.
Sign in to watch- Ticker
- CBIO
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- Cayman Islands
- Entity type
- operating
- Phone
- 617-430-5595
- Business address
- 300 FIFTH AVENUE, WALTHAM, MA, 02451
- Former names
- GLYCOMIMETICS INC
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $285,501
- in 7 filings, $286K under 10b5-1 plans
Net −$285,501. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
- Brumm Joshua T −$160K Chief Executive Officer sold 3% of stake
- McNeill Jonathan −$77K President and COO sold 3% of stake
- Pinkas Jan −$12K Chief Scientific Officer sold 3% of stake
- Im Ellie Eunkyung −$11K Chief Medical Officer sold 3% of stake
- Bispham Barbara Harlin −$11K See Remarks sold 3% of stake
Reading 48 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-12-15 | Im Ellie Eunkyung Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +65,190 | 65,190 | ||
| 2025-12-15 | Lynch Ryan See Remarks | Grant or award | +8,378 | 8,378 | ||
| 2025-12-15 | Lynch Ryan See Remarks | Grant or award | +4,000 | 12,378 | ||
| 2025-12-15 | Lynch Ryan See Remarks | Grant or award · Stock Option (Right to Buy) | +33,512 | 33,512 | ||
| 2025-12-15 | Bispham Barbara Harlin See Remarks | Grant or award | +12,422 | 12,422 | ||
| 2025-12-15 | Bispham Barbara Harlin See Remarks | Grant or award | +6,000 | 18,422 | ||
| 2025-12-15 | Bispham Barbara Harlin See Remarks | Grant or award · Stock Option (Right to Buy) | +72,185 | 72,185 | ||
| 2025-12-08 | McNeill Jonathan President and COO | Grant or award · Stock Option (Right to Buy) | +172,836 | 172,836 | ||
| 2025-12-08 | Brumm Joshua T Chief Executive Officer | Grant or award · Stock Option (Right to Buy) | +345,672 | 345,672 | ||
| 2025-12-04 | Fairmount Funds Management LLC Director | Purchase | +1,360,000 | $13.41 | $18.2M | 2,747,866 |
| 2025-12-04 | Fairmount Funds Management LLC Director | Purchase · Pre-Funded Warrant (Right to Buy) | +131,434 | $13.41 | $1.8M | 1,768,140 |
| 2025-07-16 | Pinkas Jan Chief Scientific Officer | Grant or award · Stock Option (Right to Buy) | +142,474 | 142,474 | ||
| 2025-06-23 | Moran Susan Director | Grant or award · Stock Option (Right to Buy) | +9,023 | 9,023 | ||
| 2025-06-23 | Fairmount Funds Management LLC Director | Grant or award · Stock Option (Right to Buy) | +9,023 | 9,023 | ||
| 2025-06-23 | Violin Jonathan Director | Grant or award · Stock Option (Right to Buy) | +9,023 | 9,023 | ||
| 2025-06-23 | Balcom Alexandra Director | Grant or award · Stock Option (Right to Buy) | +9,023 | 9,023 | ||
| 2025-06-23 | Lubner David Charles Director | Grant or award · Stock Option (Right to Buy) | +9,023 | 9,023 | ||
| 2025-06-13 | BVF PARTNERS L P/IL 10% owner | Other acquisition | +657,308 | 707,116 | ||
| 2025-06-13 | BVF PARTNERS L P/IL 10% owner | Other acquisition | +556,617 | 593,740 | ||
| 2025-06-13 | BVF PARTNERS L P/IL 10% owner | Other acquisition | +56,079 | 62,383 |
Page 3 of 16 · 305 trades